Clinical Trials Sponsored by Revolution Medicines, Inc.

Total 730 results

Revolution Medicines, Inc.

Recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)

United States, Italy, Spain, Malaysia, Korea, Republic of, France, Australia, Thailand, Taiwan, Poland, Singapore, Czechia, Serbia
Revolution Medicines, Inc.

Recruiting

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC)

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Revolution Medicines, Inc.

Active, not recruiting

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Solid Tumors

United States
Revolution Medicines, Inc.
Sanofi

Completed

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Solid Tumor

United States, Korea, Republic of
Revolution Medicines, Inc.
Sanofi; Amgen

Active, not recruiting

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Spain, United Kingdom, Italy, Australia, France, Germany
Revolution Medicines, Inc.
Sanofi

Active, not recruiting

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Solid Tumors

United States
Sanofi
Mirati Therapeutics Inc.; Revolution Medicines, Inc.

Active, not recruiting

Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies

Metastatic Neoplasm

Taiwan, Chile, Korea, Republic of, United States, Argentina, Australia, Netherlands, Spain
Symphony Evolution, Inc.

Terminated

Study of XL999 in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States
Symphony Evolution, Inc.

Terminated

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | AML

United States
Symphony Evolution, Inc.

Completed

Study of XL999 in Adults With Solid Tumors

Cancer

United States
Symphony Evolution, Inc.

Terminated

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Symphony Evolution, Inc.

Terminated

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States
Symphony Evolution, Inc.

Completed

Maintenance Study on the Long Term Safety of XL999

Advanced Malignancies

United States
Symphony Evolution, Inc.

Completed

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

Diabetic Nephropathy | Albuminuria

United States
Symphony Evolution, Inc.

Terminated

Study of XL999 in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Symphony Evolution, Inc.

Terminated

Study of XL999 in Patients With Multiple Myeloma

Multiple Myeloma

United States
Symphony Evolution, Inc.

Terminated

Study of XL999 in Patients With Previously Treated Ovarian Cancer

Ovarian Cancer

United States
Resolution Blue Labs Inc
Heartfulness Institute

Recruiting

Heartfulness Meditation and Corporate Burnout

Stress | Burnout | Meditation | Heartfulness

Canada
Nicholas Butowski
National Cancer Institute (NCI); Revolution Medicines, Inc.

Recruiting

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma

United States
TYK Medicines, Inc

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLC | EGFR Activating Mutation

China
TYK Medicines, Inc

Recruiting

A Study of TY-302 in Patients With Advanced Solid Tumors

Breast Cancer | Solid Tumor

China
Homology Medicines, Inc

Terminated

Natural History Clinical Study in Adult PKU

Phenylketonurias | PKU

United States
TYK Medicines, Inc

Completed

A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

Healthy Volunteers

China
TYK Medicines, Inc

Recruiting

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

NSCLC

China
TYK Medicines, Inc

Recruiting

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States
TYK Medicines, Inc

Recruiting

A Study of TY-1091 in Patients With Advanced Solid Tumors

Neoplasms | Medullary Thyroid Cancer | RET-altered Non Small Cell Lung Cancer | RET-altered Papillary Thyroid Cancer

China
TYK Medicines, Inc

Active, not recruiting

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NSCLC | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Homology Medicines, Inc

Withdrawn

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Mucopolysaccharidosis II

United States, Canada
Homology Medicines, Inc

Enrolling by invitation

Long-Term Follow Up Study of Subjects Previously Administered HMI 102

Phenylketonuria | PAH Deficiency

United States
TYK Medicines, Inc

Recruiting

A Study of TYK-00540 in Adult Patients With Solid Tumors (ASOTIAPWST)

Locally Advanced or Metastatic Solid Tumors

China
TYK Medicines, Inc

Recruiting

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

NSCLC | Brain Metastases | EGFR Activating Mutation

China
TYK Medicines, Inc

Recruiting

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

Healthy Volunteers

China
TYK Medicines, Inc

Recruiting

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumor, Adult

China
TYK Medicines, Inc

Completed

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

NSCLC

China
Homology Medicines, Inc

Terminated

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

Phenylketonuria | Phenylketonurias | PAH Deficiency

United States
Homology Medicines, Inc

Terminated

Gene Therapy Clinical Study in Adult PKU (pheNIX)

Phenylketonurias | PAH Deficiency

United States
Technoderma Medicines Inc.
Therapeutics, Inc.

Not yet recruiting

Study of TDM-180935 in Atopic Dermatitis Patients

Atopic Dermatitis

United States
Technoderma Medicines Inc.
Therapeutics, Inc.

Completed

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA) (AGA)

Alopecia, Androgenetic

United States
Technoderma Medicines Inc.
Therapeutics, Inc.

Completed

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

Alopecia, Androgenetic

United States
Technoderma Medicines Inc.
Therapeutics, Inc.

Completed

A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects

Healthy

United States
Technoderma Medicines Inc.
Therapeutics, Inc.

Completed

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Alopecia, Androgenetic

United States
Medikine, Inc.

Active, not recruiting

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)

Advanced or Metastatic Solid Tumors

United States
Disc Medicine, Inc

Active, not recruiting

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

Erythropoietic Protoporphyria

United States
OncoNano Medicine, Inc.

Completed

A Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies in Patients Undergoing Routine Surgery

Lung Cancer

United States
OncoNano Medicine, Inc.

Completed

A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Peritoneal Metastases in Patients Undergoing Cytoreductive Surgery

Peritoneal Carcinomatosis

United States
OncoNano Medicine, Inc.

Completed

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma

United States
Disc Medicine, Inc

Completed

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

Healthy Volunteer

United States

Clinical Trials Sponsored by Revolution Medicines, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations